Literature DB >> 17312831

HRT: have we changed?

O Conlon1, K McKinney.   

Abstract

BACKGROUND: In recent years, medical controversy, has surrounded the prescribing of hormone replacement therapy (HRT). AIM: This study aimed to establish whether prescribing of HRT in Northern Ireland has changed and what the current prescribing patterns are.
METHOD: A structured questionnaire was sent by post to all medical staff in Obstetrics and Gynaecology in Northern Ireland. A stamped addressed envelope was included.
RESULTS: Overall 54% of respondents indicated that they had changed their prescribing practice on HRT in the past year. The primary indication for prescribing HRT was vasomotor symptoms (93%). Fifty-six per cent of doctors recommended 1-5 years as duration of use. Oral preparations were those most commonly prescribed (57%). The dose and type chosen were the same whether prescribing had changed or not.
CONCLUSIONS: More than half of all doctors who responded had changed their prescribing practices on HRT, yet some respondents still preferred more traditional prescribing.

Mesh:

Year:  2006        PMID: 17312831     DOI: 10.1007/bf03167969

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  10 in total

1.  The national randomised trial of hormone replacement therapy in women with a history of early stage breast cancer: an update.

Authors:  Jo Marsden; Nigel Sacks
Journal:  J Br Menopause Soc       Date:  2002-12

Review 2.  Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.

Authors:  Robert Marcus; Mayme Wong; Hunter Heath; John L Stock
Journal:  Endocr Rev       Date:  2002-02       Impact factor: 19.871

3.  Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.

Authors:  P M Chavassieux; M E Arlot; C Reda; L Wei; A J Yates; P J Meunier
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

4.  Timing of estrogen replacement therapy for optimal osteoporosis prevention.

Authors:  J A Cauley; J M Zmuda; K E Ensrud; D C Bauer; B Ettinger
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

5.  Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density.

Authors:  Eva Lundström; Alexander Christow; Wendy Kersemaekers; Gunilla Svane; Edward Azavedo; Gunnar Söderqvist; Mirjam Mol-Arts; Jan Barkfeldt; Bo von Schoultz
Journal:  Am J Obstet Gynecol       Date:  2002-04       Impact factor: 8.661

6.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

7.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

Authors:  Jane A Cauley; John Robbins; Zhao Chen; Steven R Cummings; Rebecca D Jackson; Andrea Z LaCroix; Meryl LeBoff; Cora E Lewis; Joan McGowan; Joan Neuner; Mary Pettinger; Marcia L Stefanick; Jean Wactawski-Wende; Nelson B Watts
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

Review 8.  Cancer risk in menopausal women.

Authors:  Carlo La Vecchia; Louise A Brinton; Anne McTiernan
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2002-06       Impact factor: 5.237

9.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

10.  Breast cancer and hormone-replacement therapy in the Million Women Study.

Authors:  Valerie Beral
Journal:  Lancet       Date:  2003-08-09       Impact factor: 79.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.